Cécile Tissot

Cécile Tissot

Auto-generated profile, based on publicly available information

Cécile Tissot

Lawrence Berkeley National Laboratory

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TPTharick A. Pascoal
Tharick A. Pascoal
ABAndrea L. Benedet
Andrea L. Benedet
NANicholas J. Ashton
Nicholas J. Ashton
MKMin Su Kang
Min Su Kang
JTJoseph Therriault
Joseph Therriault
PRPedro Rosa-Neto
Pedro Rosa-Neto

29 May 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
BBBruna Bellaver
Bruna Bellaver
GPGuilherme Povala
Guilherme Povala
PFPamela C. L. Ferreira
Pamela C. L. Ferreira
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
DLDouglas T. Leffa
Douglas T. Leffa
TPTharick A. Pascoal
Tharick A. Pascoal
An unresolved question for the understanding of Alzheimer’s disease (AD) pathophysiology is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration. In vitro evidence suggests that reactive astrocytes unleash Aβ effects in pathological tau phosphorylation. Here, in a biomarker study across three cohorts (n = 1,016), we tested whether astrocyte reactivity modulates the association of Aβ with tau phosphorylation in CU individuals. We found that Aβ was associated with increased plasma phosphorylated tau only in individuals positive for astrocyte reactivity (Ast+). Cross-sectional and longitudinal tau–positron emission tomography analyses revealed an AD-like pattern of tau tangle accumulation as a function of Aβ only in CU Ast+individuals. Our findings suggest astrocyte reactivity as an important upstream event linking Aβ with initial tau pathology, which may have implications for the biological definition of preclinical AD and for selecting CU individuals for clinical trials.

25 April 2022 in Nature Aging
Verified
Journal Article
Open access
PDF file
JTJoseph Therriault
Joseph Therriault
TPTharick A. Pascoal
Tharick A. Pascoal
FLFiroza Z. Lussier
Firoza Z. Lussier
CTCécile Tissot
Cécile Tissot
MCMira Chamoun
Mira Chamoun
PRPedro Rosa-Neto
Pedro Rosa-Neto
Gold-standard diagnosis of Alzheimer’s disease (AD) relies on histopathological staging systems. Using the topographical information from [18F]MK6240 tau positron-emission tomography (PET), we applied the Braak tau staging system to 324 living individuals. We used PET-based Braak stage to model the trajectories of amyloid-β, phosphorylated tau (pTau) in cerebrospinal fluid (pTau181, pTau217, pTau231 and pTau235) and plasma (pTau181 and pTau231), neurodegeneration and cognitive symptoms. We identified nonlinear AD biomarker trajectories corresponding to the spatial extent of tau-PET, with modest biomarker changes detectable by Braak stage II and significant changes occurring at stages III–IV, followed by plateaus. Early Braak stages were associated with isolated memory impairment, whereas Braak stages V–VI were incompatible with normal cognition. In 159 individuals with follow-up tau-PET, progression beyond stage III took place uniquely in the presence of amyloid-β positivity. Our findings support PET-based Braak staging as a framework to model the natural history of AD and monitor AD severity in living humans.

31 August 2023 in Nature Aging
Verified
Journal Article
Open access
PDF file
WBWagner S. Brum
Wagner S. Brum
NCNicholas C. Cullen
Nicholas C. Cullen
SJShorena Janelidze
Shorena Janelidze
NANicholas J. Ashton
Nicholas J. Ashton
EZEduardo Zimmer
Eduardo Zimmer
OHOskar Hansson
Oskar Hansson
Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer’s disease (AD). Blood biomarkers can accurately detect AD pathology, but it is unclear whether their incorporation into a full diagnostic workflow can reduce the number of confirmatory cerebrospinal fluid (CSF) or positron emission tomography (PET) tests needed while accurately classifying patients. We evaluated a two-step workflow for determining Aβ-PET status in patients with mild cognitive impairment (MCI) from two independent memory clinic-based cohorts (n = 348). A blood-based model including plasma tau protein 217 (p-tau217), age and APOE ε4 status was developed in BioFINDER-1 (area under the curve (AUC) = 89.3%) and validated in BioFINDER-2 (AUC = 94.3%). In step 1, the blood-based model was used to stratify the patients into low, intermediate or high risk of Aβ-PET positivity. In step 2, we assumed referral only of intermediate-risk patients to CSF Aβ42/Aβ40 testing, whereas step 1 alone determined Aβ-status for low- and high-risk groups. Depending on whether lenient, moderate or stringent thresholds were used in step 1, the two-step workflow overall accuracy for detecting Aβ-PET status was 88.2%, 90.5% and 92.0%, respectively, while reducing the number of necessary CSF tests by 85.9%, 72.7% and 61.2%, respectively. In secondary analyses, an adapted version of the BioFINDER-1 model led to successful validation of the two-step workflow with a different plasma p-tau217 immunoassay in patients with cognitive impairment from the TRIAD cohort (n = 84). In conclusion, using a plasma p-tau217-based model for risk stratification of patients with MCI can substantially reduce the need for confirmatory testing while accurately classifying patients, offering a cost-effective strategy to detect AD in memory clinic settings.

10 August 2022 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
PFPâmela C. L. Ferreira
Pâmela C. L. Ferreira
BBBruna Bellaver
Bruna Bellaver
CTCécile Tissot
Cécile Tissot
YWYi-Ting Wang
Yi-Ting Wang
TPTharick A. Pascoal
Tharick A. Pascoal
Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer’s disease (AD) patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like protein 1 (YKL-40) levels with brain amyloid-β (Aβ) and tau pathologies. We assessed 121 individuals across the aging and AD clinical spectrum with positron emission tomography (PET) brain imaging for Aβ ([18F]AZD4694) and tau ([18F]MK-6240), as well as CSF GFAP and YKL-40 measures. We observed that higher CSF GFAP levels were associated with elevated Aβ-PET but not tau-PET load. By contrast, higher CSF YKL-40 levels were associated with elevated tau-PET but not Aβ-PET burden. Structural equation modeling revealed that CSF GFAP and YKL-40 mediate the effects of Aβ and tau, respectively, on hippocampal atrophy, which was further associated with cognitive impairment. Our results suggest the existence of distinct astrocyte biomarker signatures in response to brain Aβ and tau accumulation, which may contribute to our understanding of the complex link between reactive astrogliosis heterogeneity and AD progression.

12 November 2024 in Nature Aging
Verified
Journal Article
Open access
PDF file
JTJoseph Therriault
Joseph Therriault
SJShorena Janelidze
Shorena Janelidze
ABAndréa Lessa Benedet
Andréa Lessa Benedet
NANicholas J. Ashton
Nicholas J. Ashton
JMJavier Arranz Martínez
Javier Arranz Martínez
PRPedro Rosa-Neto
Pedro Rosa-Neto
Recently approved anti-amyloid immunotherapies for Alzheimer’s disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need for PET or CSF testing; however, their interpretation at the individual level and the circumstances requiring confirmatory testing are poorly understood. Individual-level interpretation of diagnostic test results requires knowledge of disease prevalence in relation to clinical presentation (clinical pretest probability). Here, in a study of 6,896 individuals evaluated from 11 cohort studies from six countries, we determined the positive and negative predictive value of five plasma biomarkers for amyloid-β pathology in cognitively impaired individuals in relation to clinical pretest probability. We observed that p-tau217 could rule in amyloid-β pathology in individuals with probable AD dementia (positive predictive value above 95%). In mild cognitive impairment, p-tau217 interpretation depended on patient age. Negative p-tau217 results could rule out amyloid-β pathology in individuals with non-AD dementia syndromes (negative predictive value between 90% and 99%). Our findings provide a framework for the individual-level interpretation of plasma biomarkers, suggesting that p-tau217 combined with clinical phenotyping can identify patients where amyloid-β pathology can be ruled in or out without the need for PET or CSF confirmatory testing.